Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for Nicotine Withdrawal and Smoking Reward
NCT00571805Phase 2Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of varenicline in nicotine dependence, sponsored by NYU Langone Health. Primary endpoint: Smoking reward at Day 8. Planned start Sep 2007; status: withdrawn.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00571805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571805.